Wolwo Pharma(SZ:300357)2022-12-03 10:26Financial Performance - In the first half of 2019, the company achieved operating revenue of 274.34 million CNY, a year-on-year increase of 25.43% [2] - The net profit attributable to shareholders was 130.48 million CNY, reflecting a growth of 25.53% compared to the same period last year [2] - The net profit excluding non-recurring gains and losses was 127.50 million CNY, up by 28.65% year-on-year [2] - The gross profit margin for the first half of 2019 was 96.96%, an increase of 2.62% from the previous year [5] Product Development - The company has several products under research, including "Artemisia annua powder drops" for adult allergic rhinitis, which is in the drug registration application stage, and the children's version is in Phase III clinical trials [3] - The "Dust Mite Skin Prick Diagnostic Kit" received approval for registration in March 2019 and is set to be officially produced and sold [4] - The company is expanding its product line with nine new skin prick products, which offer advantages such as shorter time and lower costs compared to blood tests [5] Market Expansion - The company’s sales network has expanded to most provincial cities and some county-level cities in China, with a growing patient base [3] - The allergic market has significant growth potential, with ongoing market education expected to further expand opportunities [3] Strategic Initiatives - The company has established a professional academic marketing team to enhance its coverage in the allergic disease sector and increase market influence through multi-level academic conferences [5] - The investment in Shanghai Iwu Stem Cell Technology Co., Ltd. aims to focus on anti-aging and regenerative medicine, leveraging advanced stem cell technologies [6] - Following a capital increase in January 2019, the registered capital of Iwu Stem Cell increased from 150 million CNY to 190.95 million CNY, with the company holding 78.55% of the equity [6]